Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览16
暂无评分
关键词
conventional dendritic cell,neoadjuvant therapy,positive breast cancer,her2,dc1
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要